Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 1980 Aug 28;303(9):473-8
Date
08/28/1980Pubmed ID
6930539DOI
10.1056/NEJM198008283030901Scopus ID
2-s2.0-0018936409 (requires institutional sign-in at Scopus site) 169 CitationsAbstract
We designed a protocol to address the problem of relapse from complete remission in acute myelogenous leukemia. Patients in remission were treated for 14 months; early and later intensification of chemotherapy, sequential drug combinations, and high-dose continuous infusions of cytarabine were included. Eighty-three consecutive patients under 50 years of age were entered into this study from February 1976 to October 1979. The rate of complete remission is 70 per cent. A Kaplan-Meier analysis predicts that 49 +/- 17 per cent of patients (mean +/- 2 S.D.) who entered complete remission will remain free of disease at two years. Durations of complete remission for patients in the 0 to 17-year and 18 to 50-year age groups are comparable.
Author List
Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG, Frei E 3rdAuthor
Bruce m. Camitta Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdult
Anti-Bacterial Agents
Blood Transfusion
Child
Child, Preschool
Cytarabine
Doxorubicin
Drug Administration Schedule
Drug Therapy, Combination
Female
Granulocytes
Humans
Infant
Leukemia, Myeloid, Acute
Male
Mercaptopurine
Methotrexate
Methylprednisolone
Middle Aged
Vincristine
